I agree with you ATL that the collaboration would be with both BMS and Merck. I do not know if combination trial with BMS has started yet or not? Please someone confirm this.
They have said many times that they have long term survival in combination trial. So, based on this I think they are far into program collaborating with Merck and the data hopefully would unbounded next year in first half. Keep in mind we are talking about rGBM here which the survival rate known to be much less than 12 months. So, we should be able to get the data very quickly. If 50% of patient living longer than 12 months that destine for approval no matter what.
In addition, people talking about the termination of trial with BMS back in 2020. If you listen carefully what Dr. LL said earlier, she mentioned that the timing of administering of the drug specially from BMS had different results. I think after that study they came back with the new one based on what they have leaned earlier and collaborating with BMS now.
News 
Market Data 
Discover 
